| FURM | PTO-1 | 1449 | U.S. Dept. of Commerce | Atty Docket No. | Serial No. | |
|------------|---------------|------------------------------------|--|-------------------------|---------------------------------------|--|
| • | | | OVP E Ratent and Trademark Office | P1192-2C1 | 10/791,618 | |
| LICT | OE DI | SCLOSURES CITED BY APPLIC | / 4\ | Applicant | | |
| | | 1 | ADD 0.7 700C | Sherman Fong | T Croup | |
| (U | lse sev | eral sheets if necessary) | APR 0 7 2006 | Filing Date 02 Mar 2004 | Group 1647 | |
| | | | | | | |
| | | UIMER " T. Trederick Mitchell " | IN VIVO Expression of the Novel CXC Ch | Perinent Pages, etc.) | al and Cancerous | |
| W /) | 15 | Human Tissue" American Jo | urnal of Pathology 156(6):1937-1950 (J | un 2000) | and concersus | |
| mΧl | | Ward, Stephen G., "Chemok | ines: understanding their role in T-ly | mphocyte biology" Bi | ochemical | |
| () | 16 | <u>Journal</u> 333:457-470 (1998) | | | | |
| | | | | | | |
| | | | | ··- | | |
| | | | | | | |
| | | \ | | | · · · · · · · · · · · · · · · · · · · | |
| . | | | | | | |
| | | | | • | • | |
| | | | • | | | |
| | | | • | | | |
| • | | | | | | |
| | | | in the second se | | • | |
| | | | · · · · · · · · · · · · · · · · · · · | | | |
| | | | | | | |
| | | · | | | | |
| | | <u> </u> | | | | |
| | | | | | | |
| | | | | | | |
| | | | • | | | |
| | | | | | | |
| | | | | | | |
| . | | | | | | |
| | | : | | | • | |
| | | | | | | |
| | | | | | | |
| | | | | | · | |
| | 1991 | | | | | |
| | | · | · · · · · · · · · · · · · · · · · · · | | | |
| | | | · | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| xamine | r .^ | h ha | | ata Cansidared | 11. | |
| | \mathcal{M} | YIUWADOX | . 0 | ate Considered | 101PM | |

| | • | Form PTO-1 | 1449 OTPE | Attorney's Docket No. 39780-1192-2C1 | 407704 040 | | | | |
|----------------------|--|--|---|---|---|------------------------------|--------------------------|---------|--|
| INFO | RMATIO | N DISCLOS | URE STATEMENT | 39780-1192-2C1 Applicant(s) | BAKER, et al. | | | | |
| | (use sev | eral sheets | if necessary) | #Filing Date: May 14, 2002 | Gro | Group Art Unit: 1647 | | | |
| | · | | FARE | SUS PATENT DOCUMENTS | | | | 94 Z. J | |
| Examiner Initials | Ref. No. | Date | Document No. | Name | Class | Subclass | Filing Dat (if approp | | |
| | 1. | 10/1998 | 5,817,306 | Haskill, et al. | | | | | |
| a * | A. | | | OREIGN PATENT DOCUMENTS | | + 1 | 7 10 10 | | |
| Examiner | Ref. | Date | Document No. | Name | Class | Subclass | Translation | | |
| Initials | No. | | | | | | YES | NO | |
| | | | | | | | | 1 | |
| | | | | | | | | | |
| | • | | (includi | OTHERIDOGUMENTS | s, etc.) | | * | | |
| Examiner Initials | Ref. No. | Title | | | | | | | |
| W) | 2. | Journal of | Immunology, Vol. 143 | t of Mixed Leukocyte Reaction and B, No. 1, pp. 356-365 (July 1989). | | | | | |
| | 3. | McDyer, et al., "Patients with Multidrug-Resistant Tuberculosis with Low CD4+ T Cell Counts Have Impaired Th1 Responses." The Journal of Immunology, Vol. 158, pp. 492-500 (1997). | | | | | | | |
| | 4. | McElrath, et al., "Cutaneous Response to Recombinant Interleukin 2 in Human Immunodeficiency Virus 1-Seropositive Individuals." <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 87, pp. 5783-5787 (1990). | | | | | | | |
| | 5. | Tyring, S., ' | "Imiquimod Applied" | Copically: A Novel Response Modif | fier," Skin Therapy L | etter, 6(6):1-4 | (March 200 | /1). | |
| MY | 6. | Zaki, et al., of Cutaneo | "Synergistic Enhanc us T Cell Lumphoma | ement of Cell-Mediated Immunity b ," J. Invest. Dermatol., Vol. 118, No. | y Interleukin-12 Plus . 2, pp. 366-371 (Feb | Interleukin- ruary 2002). | 2: Basis for | therapy | |
| | | | | | | | • | | |
| | | | | | | | | | |
| | - | | | | <u> </u> | | | | |
| | | | · | | | | | | |
| | | | • | | | | | | |
| | | | | | | - | | | |
| | | | | | | | | | |
| | | | | <u> </u> | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | - | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | [| |
| | | | | | | • | | | |
| , | | ļ- - | | | | | | | |
| | ļ | | • | | | <u>-</u> | | | |
| • | | | | | | | | | |
| | | | • | | | | | | |
| L | 1 | 1 | 1 | | 1 | | | | |
| EVASABLIŠ | _#_ | | V 61 | DATE CONSIDE | EDED. 1 1 1 1 1 1 1 | | | | |

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filling date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2239614 v1